Home / Resource Library / RITUXIMAB, LENALIDOMIDE AND ZANUBRUTINIB CHEMO-FREE REGIMEN FOLLOWED BY IMMUNOCHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA: AN INVESTIGATOR INITIATED, SINGLE ARM, PHASE 2 TRIAL
RITUXIMAB, LENALIDOMIDE AND ZANUBRUTINIB CHEMO-FREE REGIMEN FOLLOWED BY IMMUNOCHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED MANTLE CELL LYMPHOMA: AN INVESTIGATOR INITIATED, SINGLE ARM, PHASE 2 TRIAL